Indian pharmaceutical market flattened after the pandemic led to a massive upsurge in demand for drugs. The industry saw a rise in sales during the Covid spike but that settled down as the number of coronavirus cases came down, except for Q1FY2022, where the second Covid wave was dominant. This resulted in a dip in the top line of pharma companies in the successive quarters.
The Covid lockdown and supply chain disruptions have led to extreme volatility in the prices of active pharmaceutical ingredients (APIs). This is bad news for Indian pharma companies as most of them import APIs from China. The sector is poised to grow now, backed by government initiatives to reduce import reliance on APIs. How will these impact business and valuation of the pharma companies?The Indian pharmaceutical market flattened after the
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Comment & Engage with ET Prime community
Exclusive invites to Virtual Events with Industry Leaders
A trusted team of Journalists & Analysts who can best filter signal from noise